[go: up one dir, main page]

DK3180363T3 - Sirp-alpha-immunoglobulin fusionsproteiner - Google Patents

Sirp-alpha-immunoglobulin fusionsproteiner Download PDF

Info

Publication number
DK3180363T3
DK3180363T3 DK15750744T DK15750744T DK3180363T3 DK 3180363 T3 DK3180363 T3 DK 3180363T3 DK 15750744 T DK15750744 T DK 15750744T DK 15750744 T DK15750744 T DK 15750744T DK 3180363 T3 DK3180363 T3 DK 3180363T3
Authority
DK
Denmark
Prior art keywords
sirp
alpha
fusion proteins
immunoglobulin fusion
immunoglobulin
Prior art date
Application number
DK15750744T
Other languages
English (en)
Inventor
Kin-Ming Lo
Nora Zizlsperger
Aroop Sircar
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53872055&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3180363(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of DK3180363T3 publication Critical patent/DK3180363T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
DK15750744T 2014-08-15 2015-08-14 Sirp-alpha-immunoglobulin fusionsproteiner DK3180363T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462038196P 2014-08-15 2014-08-15
PCT/EP2015/068798 WO2016024021A1 (en) 2014-08-15 2015-08-14 Sirp-alpha immunoglobulin fusion proteins

Publications (1)

Publication Number Publication Date
DK3180363T3 true DK3180363T3 (da) 2019-11-04

Family

ID=53872055

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15750744T DK3180363T3 (da) 2014-08-15 2015-08-14 Sirp-alpha-immunoglobulin fusionsproteiner

Country Status (22)

Country Link
US (1) US11021694B2 (da)
EP (2) EP3643727A1 (da)
JP (1) JP6764858B2 (da)
KR (1) KR20170036796A (da)
CN (1) CN107108748A (da)
AU (1) AU2015303135B2 (da)
BR (1) BR112017002646A2 (da)
CA (1) CA2956126A1 (da)
DK (1) DK3180363T3 (da)
ES (1) ES2751915T5 (da)
HR (1) HRP20191872T1 (da)
HU (1) HUE046661T2 (da)
IL (1) IL250622B2 (da)
LT (1) LT3180363T (da)
MX (1) MX2017001712A (da)
PL (1) PL3180363T3 (da)
PT (1) PT3180363T (da)
RU (1) RU2017108203A (da)
SG (1) SG11201701189TA (da)
SI (1) SI3180363T1 (da)
WO (1) WO2016024021A1 (da)
ZA (1) ZA201701810B (da)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2931752T3 (da) 2012-12-17 2019-11-18 Trillium Therapeutics Inc Behandling af cd47+ sygdomsceller med sirp-alpha-fc-fusioner
MX2015012059A (es) * 2013-03-15 2016-01-12 Merck Patent Gmbh Anticuerpos biespecificos tetravalentes.
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
SG10202108879SA (en) 2014-02-10 2021-09-29 Merck Patent Gmbh TARGETED TGFβ INHIBITION
KR20170036796A (ko) 2014-08-15 2017-04-03 메르크 파텐트 게엠베하 Sirp-알파 면역글로불린 융합 단백질
KR20170120701A (ko) * 2015-03-05 2017-10-31 프레드 헛친슨 켄서 리서치 센터 면역조절 융합 단백질 및 그 용도
KR20180028548A (ko) 2015-08-07 2018-03-16 알렉소 테라퓨틱스 인크. Sirp-알파 도메인 또는 이의 변이체를 갖는 구조체
KR20180051651A (ko) 2015-10-01 2018-05-16 히트 바이오로직스, 인코퍼레이티드 비상동성 키메라 단백질로서의 i형 및 ii형 세포외 도메인을 인접시키기 위한 조성물 및 방법
CN107149682B (zh) * 2016-03-04 2022-01-04 复旦大学 一种靶向cd47的免疫检查点抑制剂药物组合物及其制备方法
US11649284B2 (en) * 2016-04-18 2023-05-16 Baylor College Of Medicine Cancer gene therapy targeting CD47
US11560433B2 (en) 2016-05-27 2023-01-24 Albert Einstein College Of Medicine Methods of treatment by targeting VCAM1 and MAEA
CN107459578B (zh) * 2016-05-31 2021-11-26 泰州迈博太科药业有限公司 一种靶向cd47与pd-l1的双功能融合蛋白
JP6923942B2 (ja) * 2016-07-05 2021-08-25 国立大学法人神戸大学 抗腫瘍剤
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
SG11201901307VA (en) 2016-09-29 2019-03-28 Beijing Hanmi Pharmaceutical Co Ltd Heterodimeric immunoglobulin constructs and preparation methods thereof
CN114773471A (zh) 2016-10-20 2022-07-22 天境生物科技(上海)有限公司 新的cd47单克隆抗体及其应用
EP3534964A4 (en) 2016-11-03 2020-07-15 Trillium Therapeutics Inc. IMPROVEMENT OF CD47 BLOCKING THERAPY BY PROTEASOME INHIBITORS
WO2018081898A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Improvements in cd47 blockade therapy by hdac inhibitors
CN106519036B (zh) * 2016-11-04 2019-06-11 新乡医学院 抗cd47和egfr的双功能蛋白及其制备方法与应用
PE20191080A1 (es) 2016-11-18 2019-08-20 Beijing Hanmi Pharmaceutical Co Ltd Anticuerpo biespecifico heterodimerico estructural de anticuerpo natural anti-pd-1/anti-her2 y metodo para preparar el mismo
CN108220228A (zh) * 2016-12-09 2018-06-29 上海迈泰君奥生物技术有限公司 无血清细胞培养基及高效表达重组蛋白质的方法
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
HUE057326T2 (hu) 2017-01-05 2022-04-28 Kahr Medical Ltd SIRP1 Alfa-41 BBL fúziós fehérje és eljárások annak alkalmazására
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
HRP20230937T1 (hr) 2017-01-05 2023-11-24 Kahr Medical Ltd. Pd1-41bbl fuzijski protein i metode korištenja istog
CN110234345A (zh) 2017-02-27 2019-09-13 沙塔克实验室有限公司 制备和使用基于细胞外结构域的嵌合蛋白的方法
CA3054130A1 (en) 2017-02-27 2018-08-30 Shattuck Labs, Inc. Vsig8-based chimeric proteins
WO2018157164A1 (en) 2017-02-27 2018-08-30 Shattuck Labs, Inc. Csf1r-based chimeric proteins
CN108623689B (zh) 2017-03-15 2020-10-16 宜明昂科生物医药技术（上海）有限公司 新型重组双功能融合蛋白及其制备方法和用途
AU2018236461A1 (en) 2017-03-17 2019-09-19 Fred Hutchinson Cancer Center Immunomodulatory fusion proteins and uses thereof
TWI816673B (zh) * 2017-05-08 2023-10-01 大陸商上海津曼特生物科技有限公司 雙特異性重組蛋白及其應用
WO2018226985A2 (en) * 2017-06-07 2018-12-13 Antibody Biopharm, Inc. Guided combinational therapeutic antibody
WO2019027903A1 (en) 2017-08-02 2019-02-07 Phanes Therapeutics, Inc. ANTI-CD47 ANTIBODIES AND USES THEREOF
US20200347140A1 (en) * 2017-08-30 2020-11-05 Symphogen A/S Compositions and methods for treating cancer with anti-egfr antibodies
WO2019047885A1 (en) * 2017-09-07 2019-03-14 Dingfu Biotarget Co., Ltd. IMMUNOCONJUGATES COMPRISING ALPHA REGULATORY SIGNAL PROTEIN
KR20190037164A (ko) * 2017-09-28 2019-04-05 한국과학기술연구원 신규 암 치료용 조성물
CN119264274A (zh) * 2017-10-12 2025-01-07 免疫苏醒公司 Vegfr-抗体轻链融合蛋白
CN111278865B (zh) * 2017-10-26 2023-04-25 盛禾(中国)生物制药有限公司 新的重组融合蛋白及其制备和用途
CA3044097A1 (en) * 2017-11-10 2019-05-16 I-Mab Fusion proteins containing cd47 antibodies and cytokines
US12110332B2 (en) * 2017-11-20 2024-10-08 Taizhou Mabtech Pharmaceutical Co., Ltd. Bifunctional fusion protein targeting CD47 and PD-L1
AU2018378529A1 (en) * 2017-12-04 2020-06-18 Beijing Hanmi Pharmaceutical Co., Ltd. Anti-PD-L1/anti-CD47 bispecific antibody with structure like natural antibody and in form of heterodimer and preparation thereof
WO2019109357A1 (zh) 2017-12-08 2019-06-13 杭州翰思生物医药有限公司 抗pd-1/cd47的双特异性抗体及其应用
WO2019153200A1 (zh) 2018-02-08 2019-08-15 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
AU2019235627A1 (en) * 2018-03-13 2020-10-08 Pfizer Inc. Improvements in CD47 blockade therapy by EGFR antibody
KR20200133376A (ko) 2018-03-21 2020-11-27 알렉소 온콜로지 인크. 신호-조절 단백질 알파에 대한 항체 및 사용 방법
CN110386984B (zh) * 2018-04-17 2022-04-22 杭州尚健生物技术有限公司 结合cd47蛋白的融合蛋白及其应用
CN108794641A (zh) * 2018-07-04 2018-11-13 上海科医联创生物科技有限公司 一种针对EGFRvIII的多功能融合蛋白及其应用
CA3104780A1 (en) 2018-07-11 2020-01-16 Kahr Medical Ltd. Sirpalpha-4-1bbl variant fusion protein and methods of use thereof
EP3833690B1 (en) * 2018-08-08 2024-03-27 ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Recombinant bifunctional protein targeting cd47 and her2
US10780121B2 (en) 2018-08-29 2020-09-22 Shattuck Labs, Inc. FLT3L-based chimeric proteins
EP3846855B1 (en) 2018-09-04 2024-12-04 Pfizer Inc. Cd47 blockade with parp inhibition for disease treatment
CN109535258A (zh) * 2018-10-26 2019-03-29 上海科弈药业科技有限公司 一种针对Her2+肿瘤的多功能融合蛋白及其应用
AU2019369397A1 (en) * 2018-10-29 2021-05-27 Tigatx, Inc. Compositions and methods comprising IgA antibody constructs
CN111303293B (zh) * 2018-11-14 2022-08-30 杭州尚健生物技术有限公司 一种融合蛋白及其用途
CA3115547A1 (en) * 2018-11-14 2020-05-22 Jn Biosciences Llc Multimeric hybrid fc proteins for replacement of ivig
KR20210093270A (ko) * 2018-11-15 2021-07-27 비온디스 비.브이. 인간화 항-SIRPα 항체
CN109517054B (zh) * 2018-12-04 2022-04-08 江苏东抗生物医药科技有限公司 SIRPα变体或其融合蛋白及其应用
CN109535263B (zh) * 2018-12-04 2022-06-17 江苏东抗生物医药科技有限公司 SIRPα突变体及其融合蛋白
AU2019409805A1 (en) 2018-12-21 2021-07-22 Ose Immunotherapeutics Bifunctional anti-PD-1/SIRPA molecule
AU2020233058A1 (en) * 2019-03-06 2021-09-30 Jiangsu Hengrui Medicine Co., Ltd. Bifunctional fusion protein and pharmaceutical use thereof
CN111763261B (zh) * 2019-04-02 2022-08-09 杭州尚健生物技术有限公司 一种融合蛋白及其用途
TW202104260A (zh) * 2019-04-05 2021-02-01 美商西建公司 腫瘤選擇性結合ｃｄ４７之抗體之工程
MA56045A (fr) 2019-05-31 2022-04-06 Alx Oncology Inc Méthodes de traitement du cancer avec une protéine de fusion sirpalpha-fc en association avec un inhibiteur de point de contrôle immunitaire
WO2021004480A1 (zh) * 2019-07-08 2021-01-14 南京金斯瑞生物科技有限公司 抗cd47/抗pd-1双特异抗体及其制备方法和应用
US11795210B2 (en) 2019-07-16 2023-10-24 Gilead Sciences, Inc. HIV vaccines and methods of making and using
ES2973832T3 (es) 2019-10-18 2024-06-24 Forty Seven Inc Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda
AU2020374947B2 (en) 2019-10-31 2024-11-14 Forty Seven, LLC Anti-CD47 and anti-CD20 based treatment of blood cancer
US20230002492A1 (en) * 2019-11-08 2023-01-05 Simcere (Shanghai) Pharmaceutical Co., Ltd. Anti-human programmed cell death ligand-1 (pd-l1) antibody and use thereof
JP2023509881A (ja) 2019-12-24 2023-03-10 カルナバイオサイエンス株式会社 ジアシルグリセロールキナーゼ調節化合物
AU2021219668A1 (en) 2020-02-14 2022-08-25 Gilead Sciences, Inc. Antibodies and fusion proteins that bind to CCR8 and uses thereof
US12091681B2 (en) 2020-03-27 2024-09-17 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
CN111808183B (zh) * 2020-07-25 2022-07-08 北京吉尔麦迪生物医药科技有限公司 一种靶向CD47的高亲和力SIRPα突变体及其融合蛋白
KR20230083300A (ko) * 2020-10-07 2023-06-09 셀진 코포레이션 림프계 악성 신생물 병태의 이중특이성 항체 치료
CN112708675A (zh) * 2020-12-25 2021-04-27 中山大学肿瘤防治中心 骨髓nk细胞联合mcl1抑制剂在抗白血病中的应用
CN112656941A (zh) * 2021-01-20 2021-04-16 福建医科大学附属协和医院 抗cd47单克隆抗体在制备抗阿霉素耐药的急性淋巴细胞白血病细胞的药物中应用
JP2024510989A (ja) 2021-03-12 2024-03-12 メンドゥス・ベスローテン・フェンノートシャップ ワクチン接種方法及びｃｄ４７遮断薬の使用
US20240182572A1 (en) * 2021-04-09 2024-06-06 Ose Immunotherapeutics Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
CA3216908A1 (en) 2021-05-13 2022-11-17 ALX Oncology Inc. Combination therapies for treating cancer
CN117396478A (zh) 2021-06-23 2024-01-12 吉利德科学公司 二酰基甘油激酶调节化合物
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
JP2024520593A (ja) 2021-06-23 2024-05-24 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリエルコール（ｄｉａｃｙｌｇｌｙｅｒｃｏｌ）キナーゼ調節化合物
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20230016152A (ko) * 2021-07-19 2023-02-01 주식회사유한양행 Sirp-alpha 변이체 및 이의 용도
CN115636881A (zh) * 2021-07-19 2023-01-24 百奥泰生物制药股份有限公司 基于Luciferase报告基因系统的重组嵌合膜蛋白及其应用
CN113956363B (zh) * 2021-10-13 2023-03-31 宜明昂科生物医药技术（上海）股份有限公司 靶向cd47和cd24的重组融合蛋白及其制备和用途
WO2023072217A1 (en) * 2021-10-28 2023-05-04 Guangzhou Lintonpharm Co., Ltd. Fusion proteins targeting cd3 and cd47
WO2023076983A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
CN118201941A (zh) 2021-10-29 2024-06-14 吉利德科学公司 Cd73化合物
WO2023079438A1 (en) 2021-11-08 2023-05-11 Pfizer Inc. Enhancement of cd47 blockade therapy with anti-vegf agents
JP2024545193A (ja) 2021-12-22 2024-12-05 ギリアード サイエンシーズ， インコーポレイテッド Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用
WO2023122581A2 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
FI4245756T3 (fi) 2022-03-17 2024-11-13 Gilead Sciences Inc Ikaros-sinkkisormiperheen hajotusaineita ja niiden käyttötapoja
WO2023183890A1 (en) 2022-03-24 2023-09-28 Bitterroot Bio, Inc. Multivalent sirp-alpha fusion polypeptides
EP4499146A1 (en) 2022-03-24 2025-02-05 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
EP4499837A1 (en) 2022-03-24 2025-02-05 Bitterroot Bio, Inc. Sirp-alpha fusion polypeptides with modified fc domains
TW202345901A (zh) 2022-04-05 2023-12-01 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
IL316058A (en) 2022-04-21 2024-11-01 Gilead Sciences Inc Compounds modulate KRAS G12D
WO2023213290A1 (en) * 2022-05-06 2023-11-09 Biosion Inc. Recombinant fusion protein targeting cd40 and cd47
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11807689B1 (en) * 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
WO2024015741A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
CN116041470B (zh) * 2022-08-04 2024-10-22 四川大学华西医院 具有高亲和力结合肿瘤细胞cd47的细胞膜材料及其制备方法和应用
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
WO2024061352A1 (zh) * 2022-09-23 2024-03-28 广州凌腾生物医药有限公司 分离的抗原结合蛋白及其应用
US20240254118A1 (en) 2022-12-22 2024-08-01 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
CN118546255A (zh) * 2023-02-24 2024-08-27 恒翼生物医药(上海)股份有限公司 一种靶向αvβ3和CD47的双功能融合蛋白以及其应用
WO2024193635A1 (en) * 2023-03-22 2024-09-26 Wangzhi LI Sirp variants and uses thereof
US20240383922A1 (en) 2023-04-11 2024-11-21 Gilead Sciences, Inc. KRAS Modulating Compounds
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025006720A1 (en) 2023-06-30 2025-01-02 Gilead Sciences, Inc. Kras modulating compounds
WO2025024663A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930706D0 (en) 1999-12-24 2000-02-16 Medical Res Council Composition for inhibiting macrophage activity
US20090191202A1 (en) * 2005-09-29 2009-07-30 Jamieson Catriona Helen M Methods for manipulating phagocytosis mediated by CD47
JP2009516513A (ja) 2005-11-21 2009-04-23 ラボラトワール セローノ ソシエテ アノニム ハイブリッド抗原結合分子の組成物及び製造方法並びにその使用
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
CN103242444A (zh) 2007-10-11 2013-08-14 大学健康网络 调节SIRPα-CD47相互作用以增加造血干细胞植入和用于此的化合物
EP2111869A1 (en) † 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
MX2011006621A (es) † 2008-12-19 2011-07-12 Novartis Ag Polipeptidos solubles para uso en el tratamiento de trastornos autoinmunes e inflamatorios.
HRP20240362T1 (hr) * 2009-05-15 2024-06-07 University Health Network Pripravci i postupci namijenjeni liječenju hematološkog raka, koji ciljaju na međudjelovanje između sirp-alfa i cd47
EP4134095A1 (en) 2009-09-15 2023-02-15 The Board of Trustees of the Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
HUE060541T2 (hu) 2010-05-14 2023-03-28 Univ Leland Stanford Junior Humanizált és kiméra monoklonális CD47 elleni ellenanyagok
EP2407487A1 (en) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
HUE051954T2 (hu) 2011-11-28 2021-03-29 Merck Patent Gmbh ANTI-PD-L1 ellenanyagok és alkalmazásaik
CN107880100A (zh) † 2012-01-17 2018-04-06 小利兰·斯坦福大学托管委员会 高亲和力SIRP‑α试剂
DK2931752T3 (da) 2012-12-17 2019-11-18 Trillium Therapeutics Inc Behandling af cd47+ sygdomsceller med sirp-alpha-fc-fusioner
US9873747B2 (en) * 2013-01-31 2018-01-23 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
MX2015012059A (es) 2013-03-15 2016-01-12 Merck Patent Gmbh Anticuerpos biespecificos tetravalentes.
WO2015148416A1 (en) 2014-03-24 2015-10-01 Deqiang Jing Novel recombinant bi-functional fusion proteins, preparation and use thereof
EP3188758B1 (en) 2014-08-08 2023-10-04 The Board of Trustees of the Leland Stanford Junior University Sirp alpha-antibody fusion proteins
KR20170036796A (ko) 2014-08-15 2017-04-03 메르크 파텐트 게엠베하 Sirp-알파 면역글로불린 융합 단백질

Also Published As

Publication number Publication date
IL250622A0 (en) 2017-04-30
US20160177276A1 (en) 2016-06-23
PT3180363T (pt) 2019-11-05
MX2017001712A (es) 2017-04-27
EP3180363A1 (en) 2017-06-21
IL250622B (en) 2022-12-01
HRP20191872T1 (hr) 2020-02-07
EP3180363B1 (en) 2019-09-25
JP6764858B2 (ja) 2020-10-07
IL250622B2 (en) 2023-04-01
AU2015303135A1 (en) 2017-02-23
SG11201701189TA (en) 2017-03-30
US11021694B2 (en) 2021-06-01
EP3180363B2 (en) 2022-09-14
AU2015303135B2 (en) 2021-05-20
BR112017002646A2 (pt) 2018-02-27
KR20170036796A (ko) 2017-04-03
ES2751915T5 (es) 2022-12-23
PL3180363T3 (pl) 2020-02-28
ZA201701810B (en) 2020-10-28
JP2017525698A (ja) 2017-09-07
SI3180363T1 (sl) 2020-05-29
RU2017108203A (ru) 2018-09-17
CN107108748A (zh) 2017-08-29
RU2017108203A3 (da) 2019-03-13
CA2956126A1 (en) 2016-02-18
EP3643727A1 (en) 2020-04-29
LT3180363T (lt) 2019-11-25
ES2751915T3 (es) 2020-04-02
WO2016024021A1 (en) 2016-02-18
HUE046661T2 (hu) 2020-03-30

Similar Documents

Publication Publication Date Title
DK3180363T3 (da) Sirp-alpha-immunoglobulin fusionsproteiner
DK3292141T3 (da) Fusionsproteiner
IL254516A0 (en) Proteins specific for cd137
EP3188758C0 (en) SIRP-ALPHA ANTIBODY FUSION PROTEINS
DK3344654T3 (da) Anti-lag-3-antistoffer
DK3197453T3 (da) Kimært protein
HK1232136A1 (zh) 融合蛋白
DK3157559T3 (da) Anti-axl-antistoffer
HUE060878T2 (hu) Anti-transztiretin antitestek
DK3350218T3 (da) Polyomavirus-neutraliserende antistoffer
DK3250593T3 (da) Anti-transthyretin-antistoffer
DK3145946T3 (da) Bakteriebaseret proteintilførsel
DK3237432T3 (da) Proteinfremstilling
EP3344278A4 (en) INSULIN-IMMUNOGLOBULIN FUSION PROTEINS
HUE043273T2 (hu) Fúziós fehérje
DK3099791T3 (da) Protein
DK3164410T3 (da) Protein-indvinding
CL2016002136A1 (es) Proteinas de fusión uti
LT3178931T (lt) Anti-orai1 antikūnas
DK3099793T3 (da) Protein
LT3126391T (lt) Hpa-1a antikūnai
EP3688037A4 (en) IMMUNOMODULATOR FUSION PROTEINS
DK3126521T3 (da) HNF4G-RSPO2-fusionsgen
SG11201606501PA (en) Nanobody-fluorescent protein fusion
TH1601001541A (th) โปรตีนฟิวชัน